For the majority of people with Ehlers-Danlos syndrome, life expectancy is not significantly shortened. EDS encompasses thirteen recognized subtypes, and most of them cause chronic pain, joint instability, and skin fragility without directly cutting years off a person’s life. The major exception is vascular EDS, the most dangerous subtype, where the median survival is around 51 years due to the risk of sudden arterial rupture and organ perforation. Understanding which subtype you or a family member has is what determines whether life expectancy is a real clinical concern or whether the focus should be on managing day-to-day symptoms and quality of life.
Why Vascular EDS Is Different From Other Subtypes
Vascular EDS, sometimes called EDS type IV, is caused by mutations in the COL3A1 gene, which provides the instructions for making type III collagen. This particular collagen is a structural component of blood vessel walls, the intestines, and the uterus. When it is defective, those tissues become fragile in ways that can be life-threatening. Arterial walls in vEDS patients are abnormally thin, which generates higher mechanical stress on the vessel even under normal blood pressure, raising the risk of dissection and rupture.1PubMed. Increased carotid wall stress in vascular Ehlers-Danlos syndrome This is fundamentally different from what happens in the more common hypermobile or classical subtypes, where the joints and skin bear the brunt of the problem but major blood vessels remain structurally sound.
The complications that shorten life in vEDS tend to strike without warning. Arterial dissection or rupture, intestinal perforation, and uterine rupture are the hallmark emergencies.2PubMed. Vascular Ehlers-Danlos syndrome: A multidisciplinary clinical framework for early suspicion, emergency-safe management and lifelong care A person can go from feeling fine to having a surgical emergency in minutes. Because these events can happen in young adults, vEDS carries a shortened life expectancy that is dramatically different from what people with other EDS subtypes face.
Median Survival and How It Varies
The most widely cited figure for vEDS survival comes from a large study that tracked outcomes by mutation type. Across all participants, the median survival was 51 years. But that number masks a meaningful gap between men and women: median survival for males was about 46 years, while for females it was about 54 years.3Genetics in Medicine. Survival is affected by mutation type and molecular mechanism in vascular Ehlers–Danlos syndrome (EDS type IV) The reasons for this difference are not fully understood, though hormonal influences on vascular biology and the added risks of pregnancy are suspected contributors.
The type of underlying mutation also matters. Substitutions for glycine in the triple-helical domain of the collagen molecule and acceptor site mutations were associated with median survival around 51 to 52 years. Donor site mutations, however, carried a notably worse prognosis, with a median survival of just 37 years.3Genetics in Medicine. Survival is affected by mutation type and molecular mechanism in vascular Ehlers–Danlos syndrome (EDS type IV) This is one reason genetic testing matters beyond simply confirming a diagnosis: knowing which mutation a person carries can help clinicians gauge how aggressively to pursue surveillance and preventive treatment.
A more recent clinical framework echoes the median-survival-near-51-years figure, confirming it as the current best estimate across the vEDS population as a whole.2PubMed. Vascular Ehlers-Danlos syndrome: A multidisciplinary clinical framework for early suspicion, emergency-safe management and lifelong care Whether improved awareness and earlier intervention will shift that number upward in coming decades is something researchers are actively trying to determine.
Hypermobile EDS and the Subtypes That Do Not Shorten Life
Hypermobile EDS is by far the most common form of the condition, and it does not appear to reduce life expectancy. That said, calling it “benign” would badly misrepresent what people with hEDS actually experience. Chronic widespread pain, frequent joint dislocations, fatigue, and gastrointestinal dysfunction are the norm. Many patients also develop dysautonomia, a malfunction of the involuntary nervous system that can cause dizziness, rapid heartbeat, and fainting.
There has been some concern that cardiovascular problems in hEDS could affect longevity. Researchers have found that a small percentage of hEDS patients have mitral valve prolapse or mild aortic root dilation. One study found thoracic aortic dilation in roughly 15% of combined hEDS and hypermobility spectrum disorder patients, but more than 90% of affected women had only mild dilation.4PubMed Central. Cardiovascular manifestations of hypermobile Ehlers–Danlos syndrome and hypermobility spectrum disorders Another study of 95 patients with classical or hypermobile EDS found that cardiac valve abnormalities were all trivial to mild, and none of the patients needed cardiac intervention.5Genetics in Medicine. Cardiac involvement in classical or hypermobile Ehlers–Danlos syndrome is uncommon These findings suggest that while cardiac screening is reasonable, the heart problems in hEDS are not the kind that typically threaten survival.
A separate retrospective study found lower prevalences: aortic root dilation in about 2.7% of hEDS patients and mitral valve prolapse in about 3.5%.6Frontiers in Cardiovascular Medicine. Cardiac defects of hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders: a retrospective cohort study The variation across studies likely reflects differences in how patients were screened and who was included, but the consistent pattern is that serious cardiac complications are uncommon in the hypermobile subtype.
Kyphoscoliotic EDS and Other Rare Subtypes
Among the rarer forms of EDS, kyphoscoliotic EDS stands out as another subtype where life expectancy may be affected. The condition involves progressive spinal curvature and hunching, and patients can develop vascular fragility resembling what happens in vEDS, along with an elevated risk of respiratory problems from chest-wall deformity. Both of those complications can be life-threatening over time. Because kyphoscoliotic EDS is so uncommon, there are no reliable median-survival statistics; the evidence is drawn from small case series rather than population-level data.
Other rare subtypes, including dermatosparaxis EDS, arthrochalasia EDS, and myopathic EDS, each come with distinct clinical challenges. Some carry their own risks for specific organ complications, but their rarity means that life-expectancy data simply does not exist for most of them. For any rare subtype, genetic testing and specialist evaluation are the only reliable way to understand an individual’s prognosis.
Diagnostic Delays and Why They Matter for Survival
One of the biggest obstacles to improving outcomes in vEDS is the difficulty of diagnosing it in the first place. Unlike hypermobile EDS, where bendy joints and stretchy skin often raise suspicion, vEDS can present subtly. Many patients are only identified after their first major vascular or gastrointestinal emergency. A study examining diagnostic delays in vEDS patients who presented with pulmonary hemorrhage found that misdiagnosis rates had historically been above 80%. When clinicians were specifically trained to recognize the lung-bleeding pattern, the median time to diagnosis dropped from over two years to under two months, and misdiagnosis rates fell to under 10%.7PubMed Central. Pulmonary hemorrhage as an early clue: an integrated clinical-imaging-genetic diagnostic insight for vascular Ehlers-Danlos syndrome
Genetic testing has become essential to sorting out diagnostic uncertainty. Next-generation sequencing can identify pathogenic variants in EDS-related genes even when the clinical picture is ambiguous, and it sometimes reveals actionable variants in genes associated with other vascular conditions that overlap with EDS symptoms.8Genetics in Medicine. Targeted next-generation sequencing makes new molecular diagnoses and expands genotype–phenotype relationship in Ehlers–Danlos syndrome Getting an accurate molecular diagnosis early can shift how a patient is monitored and whether preventive medication is offered, both of which have direct implications for survival.
Gastrointestinal Complications in Vascular EDS
Arterial emergencies get the most attention in vEDS, but gastrointestinal complications are a major source of illness and death as well. A 17-year retrospective study of 133 vEDS patients found that 41% had experienced at least one GI event, with colonic perforation being the first digestive event in nearly half of those affected. More than half of patients who had one GI event went on to have another. Of 85 GI surgeries performed in this population, 43% were complicated by further events, and nine deaths were attributed to GI causes.9PubMed. Natural history of gastrointestinal manifestations in vascular Ehlers-Danlos syndrome: A 17-year retrospective review
Men tended to experience their first GI event at a younger age than women, and patients carrying splice-site variants had a higher cumulative incidence of digestive complications. The recurrence rate is what makes these events especially dangerous: each surgery on fragile tissue carries its own complication risk, creating a cycle where the treatment itself can trigger new problems.
Pregnancy and Vascular EDS
Pregnancy in women with vEDS is one of the highest-risk scenarios in obstetric medicine. The uterus depends on type III collagen for structural integrity, and the massive hemodynamic changes of pregnancy put additional stress on already-fragile blood vessels. A study of 76 deliveries in vEDS patients found life-threatening complications in about 14.5% of deliveries, including arterial dissection or rupture, uterine rupture, and surgical complications. Five maternal deaths occurred, a mortality rate of 6.5% per delivery.10Genetics in Medicine. Pregnancy-related deaths and complications in women with vascular Ehlers–Danlos syndrome
A systematic review that pooled data from 412 pregnancies across multiple studies found a similar maternal mortality rate of about 5.7% per pregnancy, alongside a 13.8% miscarriage rate and an 8.8% rate of premature birth among live deliveries. Obstetric anal sphincter injuries were also markedly elevated at over 11%.11PubMed. Vascular Ehlers-Danlos syndrome and pregnancy: A systematic review These numbers are why many specialists counsel vEDS patients extensively about reproductive risks, though the decision to pursue pregnancy ultimately belongs to the patient and her family.
Surgical and Anesthetic Risks
Any surgery on a person with vEDS carries heightened danger. Tissues tear more easily, vessels are prone to catastrophic bleeding, and routine steps like placing a central venous catheter can trigger a pneumothorax or hemorrhage. Specialist perioperative guidelines emphasize that all staff involved in the patient’s care need to be aware of these risks, from the anesthesiologist to the nurses on the recovery ward.12PubMed Central. Recommendations for anesthesia and perioperative management in patients with Ehlers-Danlos syndrome(s) In particular, angiographic interventions, which involve threading catheters through blood vessels, can directly cause the dissections they are sometimes meant to evaluate.
Because of these dangers, clinical reviews have described vEDS as a contraindication to elective surgery whenever possible.13PubMed. Characteristics, Diagnosis, and Management of Ehlers-Danlos Syndromes: A Review Emergency surgery obviously cannot be avoided, but the threshold for any optional procedure should be much higher than it would be for someone without vEDS. Patients and families benefit from having this conversation with their medical team well before an emergency arises, so that plans and protocols are already in place.
Celiprolol and Efforts to Improve Survival
There is currently no cure for any type of EDS, but for vEDS specifically, one medication has shown meaningful promise. Celiprolol, a beta-blocker with some unusual pharmacological properties, was tested in a randomized trial of 53 vEDS patients. In the treatment group, 20% experienced a vascular event over the follow-up period, compared with 50% of controls, translating to a roughly 64% reduction in risk.14The Lancet. Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised trial A systematic review of the evidence around celiprolol confirmed these findings and noted consistent outcomes across multiple study designs.15PubMed Central. The Impact of Celiprolol in Vascular Ehlers–Danlos Syndrome: A Systematic Review of Current Evidence
The catch is that celiprolol is not widely available everywhere. In some countries, patients must go through special access programs or import it from abroad. It is also worth noting that the original trial, while statistically significant, was small. Clinicians generally prescribe it when they can get it, but larger confirmatory trials would strengthen the evidence base considerably.
At the basic science level, researchers have been studying the cellular signaling pathways that go haywire in vEDS blood vessels. Mouse studies have shown that vEDS aortas display excessive activity in a particular signaling chain involving ERK and PKC, pathways that are already druggable targets in other contexts.16Journal of Clinical Investigation. Targetable cellular signaling events mediate vascular pathology in vascular Ehlers-Danlos syndrome This opens the possibility of future drugs that address the disease mechanism more directly than a blood-pressure-lowering beta-blocker can.
Exercise, Physical Activity, and Risk Management
For people with vEDS, the question of how much physical activity is safe has no clean answer. Case reports document serious vascular events triggered by both competitive sports and low-intensity activities, including standard rehabilitation exercises. At the same time, total inactivity carries its own costs: deconditioning, worsened pain, and reduced quality of life. Current expert recommendations lean toward low-load, supervised physical activity, but they remain inconsistent and are based almost entirely on clinical opinion rather than controlled trials.
For people with hypermobile or classical EDS, exercise is generally encouraged. Physical therapy focused on joint stability, muscle strengthening, and proprioception is a cornerstone of management. The challenge is that overly aggressive exercise can cause dislocations and injuries, while too little exercise leads to muscle weakness that makes joints even less stable. Most patients do best with a physiotherapist who understands EDS and can tailor a program that finds the balance.
Mental Health and the Indirect Toll on Life Expectancy
When people ask about EDS and life expectancy, they are usually thinking about the physical complications. But there is growing recognition that mental health contributes to the picture as well, especially in hypermobile EDS. Chronic pain, disability, and the unpredictability of symptoms can produce severe psychological distress. Research has flagged suicidal thoughts and behaviors as an underappreciated concern in hEDS, noting that while the evidence is still limited, the association warrants much more study.17PubMed. Suicidal Behaviors in Women With the Hypermobile Ehlers-Danlos Syndrome18PubMed. Updates on the psychological and psychiatric aspects of the Ehlers-Danlos syndromes and hypermobility spectrum disorders
This matters for the life expectancy conversation because a condition does not need to cause organ failure to take years from someone’s life. Untreated depression and chronic pain together create a feedback loop that is difficult to break without coordinated care. People with EDS who have access to pain management, psychological support, and peer communities tend to report better functioning and wellbeing, though formal studies comparing survival outcomes by mental health treatment are lacking.
Gene Therapy and What Might Change in the Future
The most ambitious research aims to fix the underlying genetic defect. For vEDS, scientists have designed small interfering RNA molecules (siRNA) that can selectively silence the mutant copy of the COL3A1 gene while leaving the normal copy active. Laboratory work has also shown that certain transcription factors can boost expression of the healthy gene, increasing type III collagen production.19Cardiology in Review. Vascular Ehlers-Danlos Syndrome: Pathological Variants, Recent Discoveries, and Theoretical Approaches These approaches are still in early experimental stages and have not been tested in humans, but they represent the kind of targeted therapy that could fundamentally change the survival outlook for vEDS if the science continues to advance.
For now, clinical management remains the most important factor in how long and how well someone with EDS lives. That means getting the right diagnosis, understanding which subtype you have, working with a knowledgeable medical team, and managing both the physical and psychological dimensions of the condition. The gap between the subtypes where life expectancy is essentially normal and the one where it is substantially shortened is enormous, and knowing where you fall in that spectrum is the single most important piece of information you can have.